Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

691
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
691
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

838
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
838
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

2.5K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.5K
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

238
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
238
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

5.6K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of gloves: current evidence vs. current use.

Current opinion in infectious diseases·2026
Same author

Visibly Transparent, Near-Infrared Absorbing Nanofluids Enable High-Efficiency and Safe Laser Lithotripsy.

bioRxiv : the preprint server for biology·2026
Same author

Nosocomial SARS-CoV-2 infection in patients with cancer: A four-year experience from a tertiary cancer center.

American journal of infection control·2026
Same author

Corrigendum to "4D Flow cardiovascular magnetic resonance consensus statement: 2023 update" [Journal of Cardiovascular Magnetic Resonance 25 (2023) 40].

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance·2026
Same author

Human disturbance, preys and refuge cover shape top predator movements in anthropogenic landscapes.

Behavioral ecology : official journal of the International Society for Behavioral Ecology·2026
Same author

A Comprehensive Review of Worldwide Case Series of Neurocysticercosis and Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis.

Neuroimmunomodulation·2026

Related Experiment Video

Updated: Sep 3, 2025

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

3.6K

New interaction modalities between the pharmaceutical industry and physicians.

Judith Domínguez1, Oscar Arrieta1, Miguel A Celis1

  • 1Academia Nacional de Medicina, Comité de Ética y Transparencia en la Relación Médico-Industria (CETREMI), Mexico City, Mexico.

Gaceta Medica De Mexico
|July 27, 2022
PubMed
Summary
This summary is machine-generated.

The COVID-19 pandemic altered pharmaceutical industry promotion tactics, shifting to biased academic events promoting specific drugs over optimal patient care. Ethical considerations are proposed for physicians navigating these industry-sponsored meetings.

Keywords:
Compañías farmacéuticasCurrículum médicoDrug promotionLíder de opiniónMedical curriculumMedical meetingsOpinion leaderPharmaceutical companiesPromoción de fármacosReuniones médicas

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.8K
Author Spotlight: An Efficient and Robust Software for Automated Fusion of Multiple Preclinical Imaging Modalities
07:13

Author Spotlight: An Efficient and Robust Software for Automated Fusion of Multiple Preclinical Imaging Modalities

Published on: October 27, 2023

1.3K

Related Experiment Videos

Last Updated: Sep 3, 2025

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

3.6K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.8K
Author Spotlight: An Efficient and Robust Software for Automated Fusion of Multiple Preclinical Imaging Modalities
07:13

Author Spotlight: An Efficient and Robust Software for Automated Fusion of Multiple Preclinical Imaging Modalities

Published on: October 27, 2023

1.3K

Area of Science:

  • Medical Ethics
  • Pharmaceutical Marketing
  • Physician-Industry Relations

Background:

  • COVID-19 pandemic restrictions altered traditional pharmaceutical industry and physician interactions.
  • A shift towards unilateral drug promotion via academic events featuring invited "experts" has emerged.
  • These events may prioritize commercial interests over evidence-based, patient-centered disease management.

Purpose of the Study:

  • To analyze the ethical implications of new pharmaceutical promotion strategies.
  • To evaluate the impact of industry-sponsored academic events on medical practice.
  • To propose considerations for the medical community regarding physician-industry relationships.

Main Methods:

  • Analysis of recent trends in pharmaceutical promotion.
  • Ethical review of industry-sponsored academic events.
  • Formulation of recommendations by a National Academy of Medicine committee.

Main Results:

  • Pharmaceutical promotion has shifted to academic events with "expert" speakers.
  • These events may exhibit bias towards specific drugs, potentially neglecting alternatives.
  • The focus may shift from optimal disease care to commercial drug promotion.

Conclusions:

  • Physician-industry interactions require ethical scrutiny, especially post-pandemic.
  • Transparency and a focus on patient well-being are crucial in academic medical settings.
  • Recommendations are provided to guide physicians in navigating these evolving promotional landscapes.